Indication
Pulmonary arterial hypertension
Pulmonary arterial hypertension is a rare, progressive cardiovascular disorder classified as Group 1 pulmonary hypertension that affects the precapillary pulmonary arterial vasculature. Read more about Pulmonary arterial hypertension
135 drugs 68 manufacturers
Drugs that treat it
Common Pulmonary arterial hypertension therapies.
VENTAVIS (iloprost tromethamine)
TYVASO (treprostinil)
TYVASO INSTITUTIONAL START KIT (treprostinil/nebulizer and accessories)
TYVASO REFILL KIT (treprostinil/nebulizer accessories)
FLOLAN (epoprostenol sodium (glycine))
REMODULIN (treprostinil sodium)
REVATIO (sildenafil citrate)
REVATIO (sildenafil citrate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPulmonary arterial hypertension is a rare, progressive cardiovascular disorder classified as Group 1 pulmonary hypertension that affects the precapillary pulmonary arterial vasculature.
It is characterized by pathological vascular remodeling, vasoconstriction, endothelial cell proliferation, and thrombosis within the small pulmonary arteries.
These structural changes progressively elevate pulmonary vascular resistance and arterial pressure, increasing right ventricular afterload and eventually leading to right-sided heart failure and death.
Patients typically present with exertional dyspnea, fatigue, chest pain, syncope, and peripheral edema, and the condition can arise idiopathically, heritably, or secondary to connective tissue diseases, congenital heart defects, or certain drugs and toxins.
- nih.gov
Pulmonary arterial hypertension is a rare, progressive cardiovascular disorder classified as Group 1 pulmonary hypertension that affects the precapillary pulmonary arterial vasculature It is characterized by pathological vascular remodeling, vasoconstriction, endothelial cell proliferation, and thrombosis within the small pulmonary arteries These structural changes progressively elevate pulmonary vascular resistance and arterial pressure, increasing right ventricular afterload and eventually lea...
- medlineplus.gov
It is characterized by pathological vascular remodeling, vasoconstriction, endothelial cell proliferation, and thrombosis within the small pulmonary arteries
- medlineplus.gov
These structural changes progressively elevate pulmonary vascular resistance and arterial pressure, increasing right ventricular afterload and eventually leading to right-sided heart failure and death Patients typically present with exertional dyspnea, fatigue, chest pain, syncope, and peripheral edema, and the condition can arise idiopathically, heritably, or secondary to connective tissue diseases, congenital heart defects, or certain drugs and toxins
- nih.gov
Patients typically present with exertional dyspnea, fatigue, chest pain, syncope, and peripheral edema, and the condition can arise idiopathically, heritably, or secondary to connective tissue diseases, congenital heart defects, or certain drugs and toxins
Personalize your experience
Follow Pulmonary arterial hypertension and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.